Followers | 777 |
Posts | 81,244 |
Boards Moderated | 9 |
Alias Born | 12/25/2009 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IVRN over 300k traded on tiny 1.1m floater, could see dollars this week
IVRN over 300k traded on tiny 1.1m floater, could see dollars this week
news tiny MC SS IVRN Innoveren Scientific Announces 510(k) Submission for SkinDisc(TM) Lite
First Commercial Product Submission from Company's Robust Regenerative Medicine-Based Pipeline
CINCINNATI, OH / ACCESSWIRE / March 6, 2024 / Innoveren Scientific Inc. (OTCQB:IVRN) ("Innoveren" or the "Company"), a life science company focused on becoming a leading biotech incubator, announced today that it has submitted a 510(k) premarket filing to the U.S. Federal Food and Drug Administration (FDA) for its SkinDiscTM Lite product.
SkinDiscTM Lite provides an active and protein-rich cellular matrix that is essential for structural support and cellular attachment during the wound-healing process that can be administered in an outpatient setting. The product maintains complete wound contact and depth fill during the healing process, resulting in rapid growth of the host tissue. SkinDiscTM Lite utilizes autologous platelet-rich plasma (PRP) and platelet poor plasma concentrate, from the patient's own body, helping to mitigate any potential rejection of the product.
"The FDA submission for SkinDiscTM Lite represents a significant milestone for Innoveren Scientific in our journey to advance our new medical technologies in areas of unmet need across multiple indications," said Michael Yurkowsky, Innoveren Scientific's Chief Executive Officer. "With the use of PRP, which already has predicates in wound care cleared by the FDA, we are hopeful we will also receive clearance for SkinDiscTM Lite, allowing us to continue to advance our pipeline and submit a 510(k) submission for SkinDiscTM Ultra in the coming quarters."
Innoveren Scientific is prepared to submit a second 510(k) De Novo submission for SkinDiscTM Ultra should clearance be received for SkinDiscTM Lite. SkinDiscTM Ultra is an operating room-only product for limb salvage that utilizes bone marrow aspirate (BMA).
The Company is also making progress on advancing its BreatheEasy product, a medical device that helps patients struggling with chronic obstructive pulmonary disease (COPD), as well as other closely related diseases such as chronic bronchitis and emphysema. The Company is on track for a 510(k) De Novo submission later this year once additional clinical work has been completed.
About Innoveren Scientific Inc.
Innoveren Scientific Inc., formerly known as H-CYTE, Inc. is a life science and biotech incubator company, focused on advancing new technologies in areas of unmet need across multiple indications, with the ultimate goal of improving patient lives. The company invests in and fosters innovative technologies that are supported by a strong scientific foundation, which have relatively short timelines and low costs to achieve meaningful value inflection points. For more information about Innoveren, please visit www.InnoverenScientific.com. IVRN Security Details
Share Structure
Market Cap Market Cap
85,289
03/05/2024
Authorized Shares
500,000,000
03/04/2024
Outstanding Shares
2,584,518
03/04/2024
Restricted
1,279,698
03/04/2024
Unrestricted
1,304,820
03/04/2024
Held at DTC
1,120,229
03/04/2024
news tiny MC SS IVRN Innoveren Scientific Announces 510(k) Submission for SkinDisc(TM) Lite
First Commercial Product Submission from Company's Robust Regenerative Medicine-Based Pipeline
CINCINNATI, OH / ACCESSWIRE / March 6, 2024 / Innoveren Scientific Inc. (OTCQB:IVRN) ("Innoveren" or the "Company"), a life science company focused on becoming a leading biotech incubator, announced today that it has submitted a 510(k) premarket filing to the U.S. Federal Food and Drug Administration (FDA) for its SkinDiscTM Lite product.
SkinDiscTM Lite provides an active and protein-rich cellular matrix that is essential for structural support and cellular attachment during the wound-healing process that can be administered in an outpatient setting. The product maintains complete wound contact and depth fill during the healing process, resulting in rapid growth of the host tissue. SkinDiscTM Lite utilizes autologous platelet-rich plasma (PRP) and platelet poor plasma concentrate, from the patient's own body, helping to mitigate any potential rejection of the product.
"The FDA submission for SkinDiscTM Lite represents a significant milestone for Innoveren Scientific in our journey to advance our new medical technologies in areas of unmet need across multiple indications," said Michael Yurkowsky, Innoveren Scientific's Chief Executive Officer. "With the use of PRP, which already has predicates in wound care cleared by the FDA, we are hopeful we will also receive clearance for SkinDiscTM Lite, allowing us to continue to advance our pipeline and submit a 510(k) submission for SkinDiscTM Ultra in the coming quarters."
Innoveren Scientific is prepared to submit a second 510(k) De Novo submission for SkinDiscTM Ultra should clearance be received for SkinDiscTM Lite. SkinDiscTM Ultra is an operating room-only product for limb salvage that utilizes bone marrow aspirate (BMA).
The Company is also making progress on advancing its BreatheEasy product, a medical device that helps patients struggling with chronic obstructive pulmonary disease (COPD), as well as other closely related diseases such as chronic bronchitis and emphysema. The Company is on track for a 510(k) De Novo submission later this year once additional clinical work has been completed.
About Innoveren Scientific Inc.
Innoveren Scientific Inc., formerly known as H-CYTE, Inc. is a life science and biotech incubator company, focused on advancing new technologies in areas of unmet need across multiple indications, with the ultimate goal of improving patient lives. The company invests in and fosters innovative technologies that are supported by a strong scientific foundation, which have relatively short timelines and low costs to achieve meaningful value inflection points. For more information about Innoveren, please visit www.InnoverenScientific.com. IVRN Security Details
Share Structure
Market Cap Market Cap
85,289
03/05/2024
Authorized Shares
500,000,000
03/04/2024
Outstanding Shares
2,584,518
03/04/2024
Restricted
1,279,698
03/04/2024
Unrestricted
1,304,820
03/04/2024
Held at DTC
1,120,229
03/04/2024
yeap news tiny MC SS IVRN Innoveren Scientific Announces 510(k) Submission for SkinDisc(TM) Lite
First Commercial Product Submission from Company's Robust Regenerative Medicine-Based Pipeline
CINCINNATI, OH / ACCESSWIRE / March 6, 2024 / Innoveren Scientific Inc. (OTCQB:IVRN) ("Innoveren" or the "Company"), a life science company focused on becoming a leading biotech incubator, announced today that it has submitted a 510(k) premarket filing to the U.S. Federal Food and Drug Administration (FDA) for its SkinDiscTM Lite product.
SkinDiscTM Lite provides an active and protein-rich cellular matrix that is essential for structural support and cellular attachment during the wound-healing process that can be administered in an outpatient setting. The product maintains complete wound contact and depth fill during the healing process, resulting in rapid growth of the host tissue. SkinDiscTM Lite utilizes autologous platelet-rich plasma (PRP) and platelet poor plasma concentrate, from the patient's own body, helping to mitigate any potential rejection of the product.
"The FDA submission for SkinDiscTM Lite represents a significant milestone for Innoveren Scientific in our journey to advance our new medical technologies in areas of unmet need across multiple indications," said Michael Yurkowsky, Innoveren Scientific's Chief Executive Officer. "With the use of PRP, which already has predicates in wound care cleared by the FDA, we are hopeful we will also receive clearance for SkinDiscTM Lite, allowing us to continue to advance our pipeline and submit a 510(k) submission for SkinDiscTM Ultra in the coming quarters."
Innoveren Scientific is prepared to submit a second 510(k) De Novo submission for SkinDiscTM Ultra should clearance be received for SkinDiscTM Lite. SkinDiscTM Ultra is an operating room-only product for limb salvage that utilizes bone marrow aspirate (BMA).
The Company is also making progress on advancing its BreatheEasy product, a medical device that helps patients struggling with chronic obstructive pulmonary disease (COPD), as well as other closely related diseases such as chronic bronchitis and emphysema. The Company is on track for a 510(k) De Novo submission later this year once additional clinical work has been completed.
About Innoveren Scientific Inc.
Innoveren Scientific Inc., formerly known as H-CYTE, Inc. is a life science and biotech incubator company, focused on advancing new technologies in areas of unmet need across multiple indications, with the ultimate goal of improving patient lives. The company invests in and fosters innovative technologies that are supported by a strong scientific foundation, which have relatively short timelines and low costs to achieve meaningful value inflection points. For more information about Innoveren, please visit www.InnoverenScientific.com. IVRN Security Details
Share Structure
Market Cap Market Cap
85,289
03/05/2024
Authorized Shares
500,000,000
03/04/2024
Outstanding Shares
2,584,518
03/04/2024
Restricted
1,279,698
03/04/2024
Unrestricted
1,304,820
03/04/2024
Held at DTC
1,120,229
03/04/2024
CRFU Security Details zero dilution in long time, just need any updates to fly
Share Structure
Market Cap Market Cap
517,192
03/05/2024
Authorized Shares
200,000,000
03/05/2024
Outstanding Shares
172,397,408
03/05/2024
Restricted
142,876,000
03/05/2024
Unrestricted
29,521,408
03/05/2024
Held at DTC
12,241,512
03/05/2024
FDCT strong hands holding, loading zone, a little ask smacking goes along way % wize here
FDCT strong hands holding, loading zone, a little ask smacking goes along way % wize here
FDCT strong hands holding, loading zone
agreed uplisting is better than OTC but manipulation happens there as well
little stalemate right now i guess
FDCT nice bid support in, they start hitting the ask we can see .02s approach quickly here,
FDCT nice bid support in, they start hitting the ask we can see .02s approach quickly here,
FDCT nice bid support in, they start hitting the ask we can see .02s approach quickly here,
any progress always good to hear
Typhin
Re: None
Monday, March 04, 2024 1:46:51 PM
Post# of 59272
Just wanted to update you guys. I reached out to WPF Holdings inquiring when they expect this to go through. The response I just received right now is:
“Apologies for the delay, there is a letter/email that should be forthcoming from Careclix/VHHI by the end of the week at the latest. Then WPF Holdings & Vezbi plan to follow up with an introductory letter and go over any matters that remain.
Team WPF Holdings”
ok cool thankx
nice FDCT ready for next leg up here .02s today yet? low volume mover
nice FDCT ready for next leg up here .02s today yet? low volume mover
nice FDCT ready for next leg up here .02s today yet?
FDCT with our tiny float she moves quickly on any buying pressure Held at DTC 28,870,132 03/03/2024
FDCT with our tiny float she moves quickly on any buying pressure Held at DTC 28,870,132 03/03/2024
FDCT with our tiny float she moves quickly on any buying pressure Held at DTC 28,870,132 03/03/2024
FDCT the walk down was on very low volume, zero dilution, zero toxic, the walk back up should be very easy as well
FDCT the walk down was on very low volume, zero dilution, zero toxic, the walk back up should be very easy as well
FDCT the walk down was on very low volume, zero dilution, zero toxic, the walk back up should be very easy as well
AllStar Health Brands Inc (OTC PINK:ALST) ("AllStar" or "the Company") announces that its affiliate, Allstar Global Brands, has finalized an agreement to acquire the esteemed Italian Football Club, Sanremo. Under this arrangement, AllStar will gain a 50% ownership stake in the professional soccer team's operations. The initiative extends to the United States and Canada, with a dedicated fund of $500,000 USD allocated for youth soccer programs. Concurrently, the Sanremese Football Club has unveiled a comprehensive redevelopment plan for the Sanremo Municipal Stadium, aiming to transform it into the Sanremo Arena in Liguria, Italy. Sanremese represents a cherished soccer legacy spanning generation.
Alessandro Masu, the president of Sanremse, is an enthusiastic leader seeking a suitable North American partner to spearhead sports expansion beyond Italy's borders. This collaboration will enable AllStar to establish sports complexes in the United States and Canada, providing cutting-edge athletic training to aspiring male and female soccer players. The goal is to enhance their skills and pave the way for potential advancement into collegiate soccer programs, Major League Soccer (MLS), and/or top-tier professional football leagues in the European Union.
AllStar Health Brands Inc.:
AllStar Health Brands Inc., founded in 2017 as a Nevada Corporation, is based in Miami, Florida. It specializes in healthcare products aimed at enhancing health and enhancing quality of life. With a focus on nutritional supplements, over-the-counter remedies, and medications, AllStar serves markets in North America and Europe. The company is committed to expanding its product offerings, introducing innovative solutions for improved human health, and fostering growth through acquisitions, mergers, and collaborations.
For more information please contact:
Peter Wanner, CEO AllStarHealth Brands, Inc (ALST)
Tel: 416.918.6987
email: peterw@allstarhealthbrands.com
SOURCE: Allstar Health Brands, Inc.
as long as it takes, not selling for nothing, as thats all anyone gonna get until its trade able again
FDCT look at the volume, nothing really to go back up, and I suspect they want .25-.50s b4 small 10/1 for uplisting to Nasdaq, so weakhanded sellers arent gonna get back in any cheapper, buy the quite times for max profits, zero toxic zero dilution, one of the best pinkies 4 sure
FDCT one panic seller looks to be about done here, good ridence, stronger hands took ur shares
JTBK some luv today ask smacking
FDCT see if anyone panic sells, and can turn into panic buying just as easily
WPFH shares in my account, is all I want for now
JETBLACK Corp. ($JTBK)
@jetblackcorp
·
47m
EU steps up effort for more carbon markets worldwide 🌎
https://reuters.com/sustainability/eu-step-up-efforts-more-carbon-markets-worldwide-2024-02-13/ $JTBK
FDCT lets see where we go rest of week, a PR would not surprise me anytime here
indeed FDCT has followed the path they layed out in the PR https://www.otcmarkets.com/stock/FDCT/news/FDCTech-Provides-Updates-on-the-Definitive-Agreement-for-the-Acquisition-of-Alchemy-Group-Companies-and-Direct-Investmen?id=424097 no pumping or dilution selling BS so think we are golden for this to finalize " The Company's acquisition involves purchasing shares of Alchemy UK and Alchemy Malta from Alchemy Prime Holdings Limited and its sole shareholder, Gope S. Kundnani. Mr. Kundnani is a related and affiliated party with a controlling interest in the Company, Alchemy UK and Alchemy Malta. As a result, the Company foresees a smooth and timely regulatory approval process for the change of ownership by the Financial Conduct Authority (FCA UK) and the Malta Financial Services Authority (MFSA)."
that sound about right FDCT r/s was in plans months ago when they said uplisting to Nasdaq so we are well aware this was necessary in the near future to do that, Nasdaq opens up a huge future, dont be surprised when bashers show trying to scare out shares on our tight floater here
PRKV not sure the buying today, finally sold the handful I had left, see which way it goes next few days
FDCT we need updates 4 sure, patiently waiting fire workx
with real updates KRTL can fly high zero dilution zero toxic KRTL Security Details
Share Structure
Market Cap Market Cap
859,993
02/23/2024
Authorized Shares
1,000,000,000
02/26/2024
Outstanding Shares
71,666,072
02/26/2024
Restricted
29,806,000
02/26/2024
Unrestricted
41,860,072
02/26/2024
Held at DTC
37,596,397
02/26/2024
KRTL a little luv today